|
Vaccines and Antibody Therapeutics for HPV-related Cancers
Application
Treatment and prevention of HPV-induced malignancies.
Key Benefits
Identification of a protein expressed in a large number of HPV-induced cancers.
Antibodies have been generated that bind to the protein and potentially elicit an immune response to the cancer cells.
The antibodies can be used to develop new treatments and vaccines...
Published: 12/1/2023
Contributor(s): Rafi Ahmed, Andreas Wieland
|
|
Tumor Specific CD8 T Cell TCR Sequences of HPV-Positive Head and Neck Tumors
Application
HPV-specific CD8 TCR sequences for the treatment of HPV-positive head and neck cancer by adoptive cell therapy.
Key Benefits
HPV tumor antigen set is specific for HPV-positive head and neck cancer.
Targeting of ‘non-classical’ HPV antigens E2 and E5.
Potential to synergize and complement HPV E6/7-specific TCR therapies...
Published: 4/8/2024
Contributor(s): Rafi Ahmed, Christiane Eberhardt, Andreas Wieland
|
|
Isolation of Therapeutic cells and Framework for Adoptive Cell Therapies
Application
Isolation of therapeutic cells and framework for adoptive cell therapies based around stem-like chronic memory CD8 T cells that may be paired with PD-1 blockade.
Key Benefits
Persistent cell survival and therapeutic efficacy following rechallenge with chronic viral infection and cancer.
Strong co-treatment potential with PD-1...
Published: 4/8/2024
Contributor(s): Rafi Ahmed, Daniel Chang
|
|
Serological Test for SARS-CoV-2
Application
Clinical assay for detecting SARS-CoV-2 neutralizing antibodies.
Key Benefits
Highly specific and sensitive.
Fewer false positives than commercially available tests.
Market Summary
SARS-CoV-2 is currently causing a devastating pandemic and there is a pressing need to understand the dynamics, specificity, and neutralizing...
Published: 12/20/2023
Contributor(s): Rafi Ahmed, Mehul Suthar, John Roback, Jens Wrammert, Robert Kauffman
|
|
Antibody Therapy for Varicella Zoster Virus
Application
Human monoclonal antibodies for the treatment of varicella zoster virus (VZV).
Key Benefits
Human monoclonal antibodies can limit the spread of VZV.
gH-specific antibodies are complement-independent.
Market Summary
Varicella Zoster Virus (VZV) causes varicella, more commonly known as chickenpox. Once the illness resolves, the virus...
Published: 3/1/2024
Contributor(s): Rafi Ahmed, Nicole Sullivan
|
|
Promising Antibodies Target Virus Glycoprotein for Vaccination and Therapy
ApplicationAntibodies that bind and neutralize Ebola virus glycoprotein (GP) for use in vaccination or treatment of Ebola virus disease.Key BenefitsHigher binding affinity for Ebola virus GP than closest competitor.Can be used prophylactically or for treatment of Ebola virus disease.Market SummaryThe Ebola virus is an RNA virus with a membrane composed...
Published: 3/1/2024
Contributor(s): Rafi Ahmed, Carl Davis, Erica Ollmann Saphire
|
|
Genetic Mutation in Immune Cells for Infectious Disease and Cancer Therapy
Application
Conditional epigenetic mutation in CD8+ memory T cells as potential cell therapy for chronic viral infection and personalized cancer treatment.
Key Benefits
Blocks DNA methylation in T cells, prolonging the life and enhancing the function of these cells.
Results in faster CD62L re-expression during effector to memory cell conversion.
Delays...
Published: 1/10/2024
Contributor(s): Benjamin Youngblood, Rafi Ahmed
|
|
Cross-Reactive Antibodies Against Influenza Virus
Application
Human recombinant antibodies against influenza, including H1N1, for the development of diagnostic tests and universal flu vaccines.
Key Benefits
Broadly protective antibodies against multiple influenza strains
Market Summary
Influenza spreads swiftly and globally, causing some of the most severe pandemics in the last century. Each year,...
Published: 7/28/2023
Contributor(s): Rafi Ahmed, Patrick Wilson, Jens Wrammert
|